Clinical Trials

Clinical Trials for MTG4

Filter list of Clinical Trials

TopicTrial name of investigational drugClinical Trial ID(s)StatusOrphaCodeLink
Neuroendocrine TumoursEfficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg (CLARINET FORTE)
  • NCT02651987
  • concluded
  • ORPHA100092
Neuroendocrine TumorsEfficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors (SPINET)
  • NCT02683941
  • completed
  • ORPHA100101
Neuroendocrine TumorsEfficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. (ATLANT)
  • NCT02698410
  • completed
  • ORPHA100101
PheochromocytomaPRESCRIPT - Phenoxybenzamine Versus Doxazosin in PCC Patients
  • NCT01379898
  • concluded
  • ORPHA276621
  • ORPHA29072
Pheochromocytoma and ParagangliomaMulticenter Pheochromocytoma and Paraganglioma Evaluation (MUPPET)
  • NCT03344016
  • ongoing
  • ORPHA276621
  • ORPHA29072
Pheochromocytoma and ParagangliomaFIRSTMAPPP, Genetic variants associated with increased susceptibility to thyroid cancer
  • NCT01371201
  • ongoing
  • ORPHA276621
  • ORPHA29072
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine TumoursA study of MK-6482 Monotherapy in advanced Pheochromocytoma/Paraganglioma (PPGL) and pancreatic neuroendocrine tumors (pNET)
  • MK6482-PN015
  • ongoing
  • recruiting
  • ORPHA276621
  • ORPHA29072
PHTS tumour syndromeINSPECT (Investigation into PHTS tumor syndrome)
  • 2018-5056
  • ongoing
  • ORPHA306498
Neuroendocrine TumoursStudy of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
  • NCT02955069
  • completed
  • ORPHA877
  • ORPHA100092
  • ORPHA100101
Gastro-enteropancreatic Neuroendocrine TumorA phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in patients with, Grade 2 and Grade 3 advanced GEP-NET (NETTER-2 study)
  • NCT03972488
  • CAAA601A22301/NETTER-2
  • ongoing
  • ORPHA100092
Multiple Endocrine Neoplasia Type 1PRIME Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients
  • NCT05037461
  • starting
  • OPRPHA652
Neuroendocrine TumorsA prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somato-statin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).
  • NCT03049189
  • ITM-LET-01-COMPETE
  • ongoing
  • ORPHA100092
  • ORPHA100075
  • ORPHA506052
Pheochromocytoma/Paraganglioma, pancreatic neuroendocrine tumorsA Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET)
  • NCT04924075
  • MK6482- PN015
  • Ongoing
  • ORPHA573163
  • ORPHA97253
TopicTrial name of investigational drugClinical Trial ID(s)StatusOrphaCodeLink

An overview of all Clinical Trials can be found here.